Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, . Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development ...
Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement ...
If you are a healthcare professional or a patient seeking to report an adverse event, please call 1-800-265-7927 to speak with a Sanofi Medical Information agent or click here to visit Sanofi Medical ...
헬스케어 분야에서 미충족 수요가 있는 곳에 교육 및 의약품 접근성 향상, 질환인식개선을 위해 노력합니다. 이를 위해 환자를 Care하며, 건강을 Protect하고, 사회를 Engage하는 사회책임활동을 ...
New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, . Sanofi advances its ambition to protect ...
이전에 2차 이상의 전신 요법에 실패한 만성 이식편대숙주 질환이 있는 성인 및 12세 이상의 소아 환자의 치료 ...
Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. Third quarter 2025 results will ...
Sanofi’s commitment to society is long-term, and a longstanding legacy. Our commitment translates into a set of actions to make a positive impact on the lives of people and communities around the ...
Paris, France, le 26 Septembre 2024. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q3 2024 Aide mémoire ». Résultats du troisième ...
Samarbete mellan industri och vårdpersonal gynnar patienterna. Det är en relation som har resulterat i många innovativa mediciner och som har förändrat hur flertalet sjukdomar påverkar våra liv. 1 ...
100% of developing countries work towards the UNFCCC goal of having their NAPs in place by 2025, with all new NAPs including specific health targets reflecting national and sub-national priorities.
100 % des pays en développement œuvrent pour atteindre l'objectif de la CCNUCC d'avoir leurs PNA (Plans nationaux d'adaptation) en place d'ici 2025, avec l'inclusion dans chaque nouveau PNA ...